Pioneering MD Anderson Physician-Scientist Dies at 76
Waun Ki Hong, MD, a pioneering medical oncologist who was named a 2018 OncLive Giants of Cancer Care® award winner in recognition of his practice-changing research in head and neck cancer, died at his home in California on January 2 at the age of 76.
MD Anderson Notes Passing of Waun Ki Hong: Innovator, Mentor, Colleague
Waun Ki Hong, MD, a trail-blazing physician-scientist, mentor, and 2018 Giant of Cancer Care® in Head and Neck Cancers, whose clinical research innovations led to successful organ-sparing cancer treatment, advanced the field of targeted therapy and launched chemoprevention, died Wednesday at his home in California.
Dr. Andreeff Discusses Promise of Venetoclax in AML
December 21st 2018Michael Andreeff, MD, PhD, chair of genetics, professor of medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in acute myeloid leukemia.
Dr. Overman on Next Steps With Immunotherapy in mCRC
December 20th 2018Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.
Dr. Verstovsek on JAK Inhibition in Polycythemia Vera
November 26th 2018Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.
Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC
November 17th 2018Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).
Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers
October 12th 2018Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.
Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC
October 11th 2018Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.
Dr. Allison Discusses the Future of Immunotherapy in Cancer Care
October 2nd 2018James P. Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the future of immunotherapy in the treatment of patients with cancer.
Dr. Coleman on the Future of PARP Inhibitors in Ovarian Cancer
September 29th 2018Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of PARP inhibitors in patients with ovarian cancer.
Coleman Covers Next Steps in Recurrent Ovarian Cancer
September 18th 2018Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.